Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Juli 2018 10:45 ET | Quelle: Agios Pharmaceuticals, Inc.

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- - Approval of TIBSOVO® was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission (CR) and CR with Partial Hematologic...
26. Juni 2018 08:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

- Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients...
18. Juni 2018 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
04. Juni 2018 09:00 ET | Quelle: Agios Pharmaceuticals, Inc.

New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

- Safety Profile of Combination Therapies Consistent with Single Agent IDHm Inhibitors and Azacitidine - - ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular...
02. Juni 2018 16:05 ET | Quelle: Agios Pharmaceuticals, Inc.

Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent

- In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+CRh Rate of 31.8% with a Median Duration CR+CRh of 8.2 Months - - Updated Data Suggest that R/R AML Patients with...
01. Juni 2018 16:15 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors

- Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperative Study - - Evidence of Prolonged Disease Control Observed in...
16. Mai 2018 17:02 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios to Present New Clinical Data from its IDH Programs at ASCO

– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations – – New Data From Fully...
04. Mai 2018 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day

– Commercial Infrastructure In Place Ahead of August 21, 2018 PDUFA Action Date for TIBSOVO® (Ivosidenib) for IDH1m R/R AML – – Clinical Portfolio Advancing with Four Compounds in Development and...
27. April 2018 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018

CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
11. April 2018 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018

CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...

Vorherige Seite

Nächste Seite